Ghazaleh Ghobadi
Overview
Explore the profile of Ghazaleh Ghobadi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
368
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Schie M, van Houdt P, Ghobadi G, Pos F, Walraven I, de Boer H, et al.
Front Oncol
. 2019 Dec;
9:1264.
PMID: 31867266
Quantitative MRI reflects tissue characteristics. As possible changes during radiotherapy may lead to treatment adaptation based on response, we here assessed if such changes during treatment can be detected. In...
2.
van Houdt P, Ghobadi G, Schoots I, Heijmink S, De Jong J, van der Poel H, et al.
J Magn Reson Imaging
. 2019 Oct;
51(4):1235-1246.
PMID: 31588646
Background: Previous studies have reported tumor volume underestimation with multiparametric (mp)MRI in prostate cancer diagnosis. Purpose: To investigate why some parts of lesions are not visible on mpMRI by comparing...
3.
Fernandes C, Simoes R, Ghobadi G, Heijmink S, Schoots I, De Jong J, et al.
Int J Radiat Oncol Biol Phys
. 2019 May;
105(1):140-148.
PMID: 31085288
Purpose: Focal salvage treatments of recurrent prostate cancer (PCa) after radiation therapy require accurate delineation of the target volume. Magnetic resonance imaging (MRI) is used for this purpose; however, radiation...
4.
Fernandes C, van Houdt P, Heijmink S, Walraven I, Keesman R, Smolic M, et al.
J Magn Reson Imaging
. 2018 Dec;
50(1):269-278.
PMID: 30585368
Background: Post-radiotherapy locally recurrent prostate cancer (PCa) patients are candidates for focal salvage treatment. Multiparametric MRI (mp-MRI) is attractive for tumor localization. However, radiotherapy-induced tissue changes complicate image interpretation. To...
5.
Fernandes C, Ghobadi G, van der Poel H, De Jong J, Heijmink S, Schoots I, et al.
Eur Radiol
. 2018 Nov;
29(8):4160-4168.
PMID: 30421016
Objectives: Diagnosis of radio-recurrent prostate cancer using multi-parametric MRI (mp-MRI) can be challenging due to the presence of radiation effects. We aim to characterize imaging of prostate tissue after radiation...
6.
van Houdt P, Agarwal H, van Buuren L, Heijmink S, Haack S, van der Poel H, et al.
Magn Reson Med
. 2017 Jul;
79(3):1586-1594.
PMID: 28671331
Purpose: To evaluate the performance of a multi-echo spin-echo sequence with k-t undersampling scheme (k-t T ) in prostate cancer. Methods: Phantom experiments were performed at five systems to estimate...
7.
van Schie M, Steenbergen P, Dinh C, Ghobadi G, van Houdt P, Pos F, et al.
Phys Med Biol
. 2017 May;
62(14):5575-5588.
PMID: 28557799
Dose painting by numbers (DPBN) refers to a voxel-wise prescription of radiation dose modelled from functional image characteristics, in contrast to dose painting by contours which requires delineations to define...
8.
Dinh C, Steenbergen P, Ghobadi G, van der Poel H, Heijmink S, De Jong J, et al.
Med Phys
. 2017 Jan;
44(3):949-961.
PMID: 28039927
Purpose: Tumor localization provides crucial information for radiotherapy dose differentiation treatments, such as focal dose escalation and dose painting by numbers, which aim at achieving tumor control with minimal side...
9.
Ghobadi G, De Jong J, Hollmann B, van Triest B, van der Poel H, Vens C, et al.
Radiother Oncol
. 2016 Feb;
119(1):97-103.
PMID: 26897517
Purpose: To evaluate the impact of GTV-CTV dose differentiation by simulating response of prostate patients to radiotherapy, considering histopathology of prostatectomy specimens. Material And Methods: Tumors' cell numbers (N0) and...
10.
Dinh C, Steenbergen P, Ghobadi G, Heijmink S, Pos F, Haustermans K, et al.
Phys Med
. 2016 Feb;
32(3):446-51.
PMID: 26858164
For radiotherapy of prostate cancer, MRI is used increasingly for delineation of the prostate gland. For focal treatment of low-risk prostate cancer or focal dose escalation for intermediate and high-risk...